Erythropoietin administration to preterm infants: Comparison between subcutaneous and intravenous route;Érythropoïétine chez le nouveau-né: Efficacité comparée des voies d'administration sous-cutanée et intraveineuse

Archives de Pediatrie

Volumn 11, Issue 4, 2004, Pages 319-326

  Rigourd, V ^a   Kieffer, F ^a   Dommergues, M A ^a   Ayachi, A ^a   Assaf, Z ^a   Mohamed, I ^a   Voyer, M ^a   Magny, J F ^a  

^a Institut de Puericulture   (France)

Author keywords

An mie; Anemia, neonatal; rythropo tine humaine recombinante; Erythropoietin, recombinant, administration and dosage; Infant, premature; Pr matur

Indexed keywords

FERRITIN; RECOMBINANT ERYTHROPOIETIN; HEMOGLOBIN;

ABSORPTION; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVALUATION; FEMALE; FILTRATION; HOSPITALIZATION; HUMAN; INFANT; INFORMATION PROCESSING; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PARENTERAL NUTRITION; PREMATURITY; RETICULOCYTE COUNT; RETROSPECTIVE STUDY; COMPARATIVE STUDY; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NEWBORN; SUBCUTANEOUS DRUG ADMINISTRATION; TOTAL PARENTERAL NUTRITION; TREATMENT OUTCOME;

ANEMIA; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; PARENTERAL NUTRITION, TOTAL; RETICULOCYTE COUNT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 1842423103     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcped.2003.12.025     Document Type: Article

References (31)

1. Bifano E.M., Curran T.R. Minimizing donor blood exposure in the neonatal intensive care unit: current trends and future prospects. Clin Perinatol. 22:1995;657-669.
2. Stockman J.A. 3rd, Graeber J.E., Clarck D.A., McClellan K., Garcia J.F., Kavey R.E. Anemia of prematurity: determinants of the erythropoietin response. J Pediatr. 105:1984;786-792.
3. Maier R.F., Obladen M., Scigalla P., Linderkamp O., Duc G., Hieronimi G., et al. The effect of epoietin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth weight infants. N Engl J Med. 330:1994;1173-1178. European Multicentre Erythropoietin Study Group.
4. Huynh-Delerme C., Penaud J.F., Lacombe C., Brunhes A., Moriette G. Stability and biological activity of epoietin beta in parenteral nutrition solutions. Biol Neonate. 81:2002;158-162.
5. Brown M.S., Jones M.A., Ohls R.K., Christensen R.D. Single-dose pharmacokinetics of recombinant human erythropoietin in preterm infants after intravenous and subcutaneous administration. J Pediatr. 122:1993;655-657.
6. Shannon K.M., Keith J.F. 3rd, Mentzer W.C., Ehrenkranz R.A., Brown M.S., Widness J.A., et al. Recombinant human erythropoietin stimulates erythopoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics. 95:1995;1-8.
7. Messer J., Escande B., Kuhn P., Matis J. Utilisation de l'érythopoïétine dans l'anémie du pré maturé Mtp pédiatrie. 4:2001;305-307.
8. Klosowski S., Kongolo G., Morisot C., Thelliez P., Djebara A., Deboubaix P. Prévention de l'anémie du prématuré: place de l'érythropoïétine humaine recombinante dans un service de néonatologie de niveau II. Arch Pédiatr. 6:1999;592-594.
9. Trentesaux A.S., Egreteau L., Santerne B., Morville P. Érythropïétine humaine recombinante chez le nouveau-né prématuré. Évaluation d'une année d'expérience. Arch Pediatr. 6:1999;944-951.
10. Ohls R.K., Ehrenkranz R.A., Wright L.L., Lemons J.A., Korones S.B., Stoll B.J., et al. Effects of early erythropoietin therapy on the transfusion requirement of preterm infants below 1250 grams birth weight: a multicentrer, randomized, controlled trial. Pediatrics. 108:2001;934-942.
11. Franz A.R., Pohlandt F. Red blood cell transfusions in very and extremely low birthweight infants under restrictive transfusion guidelines: is exogenous erythropoietin necessary? Arch Dis Child Fetal Neonatal Ed. 84:2001;F96-F100.
12. es Journées nationales de néonatologie. 1998;217-225 (Karger), Paris.
13. Strauss R.G. Managing the anemia of prematurity: red blood cell transfusions vs recombinant erythropoietin. Transfusion Med Rev. 15:2001;213-223.
14. Bader D., Kugelman A., Maor-Rogin N., Weinger-Abend M., Hershkowitz S., Tamir A., et al. The role of high-dose oral iron supplementation during erythopoietin therapy for anemia of prematurity. J Perinatol. 21:2001;215-220.
15. Kumar P., Shankaran S., Krishnan R.G. Recombinant human erythropoietin therapy for treatment of anemia of prematurity in very low birth weight infants: a randomized, double-blind, placebo-controlled trial. J Perinatol. 18:1998;173-177.
16. Meyer M.P., Meyer J.H., Commerford A., Hann F.M., Sive A.A., Moller G., et al. Recombinant human erythopoietin in the treatment of the anemia of prematurity: results of a double-blind, placebo-controlled study. Pediatrics. 93:1994;918-923.
17. Bader D., Blondheim O., Jonas R., Admoni O., Abend-Winger M., Reich D., et al. Decreased ferritin levels, despite iron supplementation, during erythopoietin therapy in anemia of prematurity. Acta Paediatr. 85:1996;496-501.
18. Sans T., Joven J., Vilella E., Masdeu G., Farre M. Pharmacokinetics of several subcutaneous doses of erythropoietin: potential implications for blood transfusion. Clin Exp Pharmacol Physiol. 27:2000;179-184.
19. Besarad A. Physiological and pharmacodynamic considerations for route of EPO administration. Semin Nephrol. 20:2000;364-374.
20. Vamvakas E.C., Strauss R.G. Meta-analysis of controlled clinical trials studying the efficacy of rHuEpo in reducing blood transfusions in the anemia of prematurity. Transfusion. 41:2001;406-415.
21. Maier R.F., Obladen M., Muller Hansen I., Kattner E., Merz U., Arlettaz R., et al. Early treatment with erythropoietin β ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000g. J Pediatr. 141:2002;8-15.
22. Ohls R.K., Veerman M.W., Christensen R.D. Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in total parenteral nutrition solution. J Pediatr. 128:1996;518-523.
23. Ohls R.K., Harcum J., Schibler K.R., Christensen R.D. The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double-blind, placebo-controlled study. J Pediatr. 131:1997;661-665.
24. Stevens B., Yamada J., Ohlsson A. Sucrose for analgesia in newborn infants undergoing painful procedures. Cochrane Database Syst Rev. 4:2001;. CD0011069.
25. Macdougall L.C. Novel erythropoiesis stimulating protein. Semin Nephrol. 20:2000;375-381.
26. Ohls R.K. Human recombinant erythropoietin in the prevention and treatment of anemia of prematurity. Paediatr Drugs. 4:2002;111-121.
27. Krishnan R., Shankaran S., Krishnan M., Kauffman R.E., Kumar P., Lucena J. Pharmacokinetics of erythropoietin following single-dose subcutaneous administration in preterm infants. Biol Neonate. 70:1996;135-140.
28. Ohls R.K. Erythropoietin treatment in extremely low birth weight infants: blood in vs. blood out. J Pediatr. 141:2002;3-6.
29. Haÿs S., Guy B., Boulard M.S., Bourgeois J., Blondet C., Putet G. Transfusion malgré érythropoïétine recombinante: échec ou limites du traitement ? Étude d'une cohorte annuelle de poids de naissance inférieur à 1500 g. Arch Pediatr. 8:2001;355-360.
30. Ohl R.K. The use of erythropoietin in neonates. Clin Perinatol. 27:2000;681-696.
31. Asch J., Wedgwood J.F. Optimizing the approach to anemia in preterm infant: is there a role for erythopoietin therapy? J Perinatol. 17:1997;276-282.